A Phase I Trial of Single-Agent LY2780301 in Patients With Advanced or Metastatic Cancer.
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2015
At a glance
- Drugs LY 2780301 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 30 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.as reported by ClinicalTrials.gov.
- 30 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 02 Jul 2012 Planned End Date changed from 1 May 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.